Presseinformationen weltweit an Journalisten und Leser verbreiten
IMA203CD8 is a 2nd-generation product candidate co-expressing Immatics’ proprietary CD8αβ co-receptor engaging functional CD4 and CD8 T cells directed against PRAME Preclinical data with IMA203CD8 showed enhanced potency and prolonged anti-tumor activity mediated by activated TCR-engineered CD4 T cells Mehr
Immatics N.V. (Nasdaq: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the two companies have entered into a strategic research Mehr
Dose escalation for cell therapy candidate ACTengine® IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer types, with 8/13 responders (62%) treated Mehr
ACTengine® patient recruitment remains on track; as of end of July, a total of 27 patients have been treated with IMA201, IMA202 or IMA203 across different cancer indications TCR Bispecifics pipeline advancing with progress towards clinical trial initiation of IMA401 and preclinical proof-of-concept for second TCER® molecule IMA402 Cash and cash equivalents as well as Other financial assets of $229.1 million1(€192.8 million) as of June 30, 2021, funding company operations into 2023 Immatics N.V. (NASDAQ: IMTX; “Immatics”), a Mehr
Immatics’ second TCR Bispecifics program IMA402 demonstrates tumor cell killing in vitro and complete regressions of established tumors in an in vivo tumor model IMA402 targets an Immatics–validated peptide derived from PRAME, one of the most frequently expressed intracellular cancer targets for TCR therapy Immatics has selected a clinical lead candidate for the IMA402 program and initiated manufacturing activities Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T Mehr
Phase 1a data update from clinical ACTengine® programs demonstrated first anti-tumor activity at early phases of dose escalation in heavily pre-treated solid cancer patients Enrollment across clinical ACTengine® IMA200 trial series continues to scale up Cash and cash equivalents as well as Mehr
ACTengine® IMA200 clinical trial series continues scaling globally; initial analysis for patients in ACTengine® dose escalation is on track for Q1 2021 Expansion of UTHealth partnership secures cell therapy manufacturing capacities until end of 2024 Positive pre-clinical data updates on Mehr
<p> </p> <ul type="disc"> <li>Multi-target Adoptive Cell Therapy (ACT) with endogenous T cells against defined pHLA targets demonstrates feasibility, tolerability and high T-cell persistence.</li> <li>Clinical courses observed in patients indicate COL6A3 exon 6 as a potentially valuable tumor target for continued Mehr
Immatics’ first TCR Bispecific program IMA401 delivers preclinical proof-of-concept demonstrating complete remissions of transplanted human tumors in mice and favorable CMC characteristics The IMA401 target, an HLA-A*02-bound peptide derived both from MAGEA4 and MAGEA8, shows >5-fold higher target peptide levels Mehr
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the appointment of Eliot Forster, PhD, to its Board of Directors. Forster currently serves as Chief Executive Mehr